Company news

Nurix Therapeutics, Inc. news in 2023

Nurix Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

December 10, 2023

Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting

December 3, 2023

Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting

November 1, 2023

Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial

October 31, 2023

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

October 11, 2023

Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics

September 6, 2023

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

July 12, 2023

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

June 13, 2023

Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

May 8, 2023

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations

April 16, 2023

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

April 12, 2023

Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479

March 19, 2023

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting

March 13, 2023

Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 5, 2023

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update

February 8, 2023

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

January 8, 2023

Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Decks in 2023